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Abstract 
Multidrug resistance (MDR) is a major limitation in the successful treatment of cancer 
using chemotherapy. Cancers can be intrinsically resistant or develop resistance during 
treatment to a variety of structurally and functional unrelated drugs. Numerous cellular 
mechanisms which contribute to MDR have been identified, however, the most common 
mechanism is the over expression of a 170kDa glycoprotein referred to as P-glycoprotein 
(P-gp). P-gp acts as an ATP-dependant drug efflux pump and is encoded by the MDRI gene. 
An understanding of the regulation of the MDRI gene is essential if the clinical impact of 
MDR is to be reduced. However, at this stage how this gene is regulated in vivo remains 
elusive. Amplification of the MDRI gene or an increase in mRNA stability may increase 
expression in cells already expressing P-gp, though they do not account for activation 
and/or regulation of the MDRI gene itself. Hence the focus of many studies is on the 
regulation of MDRI transcription. 
The current study investigated the role of intron 1 in MDRI promoter regulation. The intron 
1 region has been shown to contain a CpG island which is differentially methylated in the 
drug sensitive HL60 cells and completely unmethylated in MDR HlE8 cells. In vitro 
DNA:protein interactions were found to exist within this differentially methylated region. 
Thus the aim of the current study was to determine the functional role of the downstream 
CpG island in MDRI regulation in cells of varying origin and varying MDR levels. The 
MDR cells lines studied were the HL60 derived HlE8 leukaemic cell line, the K562 derived 
Kepru leukaemic cell line, the KB-3-J derived KB-8-5 cervical cancer cell lines and the 
Lo Vo and L/ ADR colon cancer cell lines. Reporter gene studies indicated an overall 
negative role in reporter activity for the +283 to +606bp region in the leukaemic MDR cell 
lines, whilst the same region was shown to increase reporter activity in the KB-8-5 cells. 
The colon LoVo and L/ADR cells also showed an increase in activity for the +283 to 
+606bp, however, the increase was not found to be significant. Further subdivision of the 
+283 to +606bp region suggested the existence of several different potential and repressor 
and enhancer regulatory elements in the HlE8, Kepru and KB-8-5 MDR cell lines. 
XVI 
Similarly, reporter gene functional studies of the +65 to +282bp region resulted in an 
overall inhibitory effect in reporter gene activity in the HlE8 cells and a stimulatory effect 
in the KB-8-5 , LoVo and L/ADR MDR cell lines. Further subdivision of the +65 to +282bp 
region revealed several different potential repressor and enhancer elements in the cell lines 
tested . This region had not been previously investigated for DNA:protein interactions. 
UV in vivo footprinting was used to investigate in vivo chromatin structure and potential 
DNA :protein interactions in intron 1 of the MDRl gene. Sites of hypersensitivity and 
protection were found in intron 1 in all cell lines, however, it is hypothesised that some of 
the sites observed relate directly to chromatin structure as opposed to specific transcription 
factor DNA bind ing. For example a region of concentrated protection, possibly due to a 
positioned nucleosome was fo und to exist in the drug sensitive cells, whilst this same 
region was less and less protected in the more drug resistant cells. Furthermore, an increase 
in the number of hypersensitive sites was observed in the more drug resistant cell lines 
which may be due to RNA polymerase II pausing. However, many of the protected sites 
were also found throughout the intron I region , including some with the previously 
observed in vitro DNA footprints , providing further evidence that intron 1 is involved in the 
regulation of the MDRI gene. A comparison of the locations of the in vivo footprints with 
those of transcription factor consensus binding sites suggests many possible candidates for 
intron 1 mediated MDRI regulation that can be followed up in future studies. This study is 
the first to provide in vivo evidence for specific and structural features and possible 
transcription factor mediated regulation in intron 1 of the MDRl gene. 
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